%0 Journal Article
%T A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
%A Zhang, Yong
%A Ye, Ling
%A Zhang, Huijun
%A Chen, Xuehua
%A Ji, Haiying
%A Chen, Gang
%A Zhang, Lu
%A Zhang, Tengfei
%A Jin, Meiling
%J Journal of Thoracic Disease
%D 2018
%B 2018
%9 
%! A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
%K 
%X Lung cancer is the leading cause of cancer death worldwide (1). Non-small cell lung cancer (NSCLC) causes 85% of the cases, and small cell lung cancer (SCLC) accounts for the other 15% (2). Activating alterations of  epidermal growth factor receptor  ( EGFR ) lead to 10–15% and 30–40% of NSCLC, especially adenocarcinoma, in Caucasus and Asian patients (3). In contrast, EGFR mutations are extremely rare in SCLC (4). However, some patients exhibit a combination subtype of SCLC and adenocarcinoma with EGFR mutation, which have been poorly investigated in terms of effective targeted therapeutic strategy.
%U https://jtd.amegroups.org/article/view/24487
%V 10
%N 10
%P E739-E743
%@ 2077-6624